Safety

JYSELECA - A JAK1 preferential inhibitor for moderate to severe RA1

Acceptable Tolerability1-3

‘JYSELECA Journeys’ by Film JYSELECA


Episode 3 - Facing Adversity

Discover Strength of Balance


Frequency based on placebo-controlled pre-rescue period (week 12) pooled across FINCH 1 and 2, and DARWIN 1 and 2, for patients who received JYSELECA 200 mg.

For complete information regarding the safety and use of JYSELECA, please refer to the Summary of Product Characteristics and Risk Management Materials which can be found here.


For complete information regarding the safety and use of JYSELECA, please refer to the Summary of Product Characteristics and Risk Management Materials which can be found here.


For complete information regarding the safety and use of JYSELECA, please refer to the Summary of Product Characteristics and Risk Management Materials which can be found here.

Low rates* of JAK inhibitor-associated adverse events1,2†


Similar observed rates of serious infections, Herpes Zoster and VTE compared to adalimumab3

*Based on AE rates observed as ‘Uncommon’ (<1% and ≥0.1%) or of lower frequency in the JYSELECA clinical trials.1,2

†JAK inhibitor-associated adverse events defined as VTEs, Herpes Zoster reactivation and serious infections.4

Related Content


JYSELECA is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs).1 JYSELECA may be used as monotherapy or in combination with methotrexate (MTX).1

References: 1. JYSELECA SPC. Available at: www.medicines.org.uk / www.medicines.ie. Last accessed: November 2022. 2. Winthrop K, et al. Arthritis Rheumatol 2021;73(suppl 10). Available at: https://acrabstracts.org/abstract/integrated-safety-analysis-update-for-filgotinib-in-patients-with-moderately-to-severely-active-rheumatoid-arthritis-receiving-treatment-over-a-median-of-2-2-years/. Last accessed November 2022. 3. Combe B, et al. Ann Rheum Dis 2021;doi:10.1136/annrheumdis-2020-21921. 4. Angelini J, et al. Biomolecules 2020;10(7):E1002. doi: 10.3390/biom10071002. 5. Genovese MC, et al. Poster presented virtually at the European League Against Rheumatism (EULAR) 2020 E-Congress, July 3–6, 2020.

UK-RA-JY-202203-00019  | Date of preparation December 2022